Status:

COMPLETED

ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma

Lead Sponsor:

Lymphoma Study Association

Collaborating Sponsors:

Fondation ARC

Conditions:

Lymphoma, Large-Cell, Diffuse

Eligibility:

All Genders

18-60 years

Phase:

PHASE2

PHASE3

Brief Summary

The primary objective of the study is to evaluate the efficacy of ASCT as consolidation in case of bcl-2 overexpression in non previously treated patients aged 60 years or less with low-intermediate r...

Eligibility Criteria

Inclusion

  • Patient with diffuse large B-cell lymphoma according to the WHO classification (anti CD20 labeling)
  • Aged 18 to 60 years
  • Non previously treated
  • With one and only one of the following adverse characteristics: ECOG performance status 2 or more, or Ann Arbor stage III or IV, or elevated LDH level
  • Negative HIV, HBV and HCV serologies (except vaccination)
  • With a minimum life expectancy of 3 months
  • Having previously signed a written informed consent

Exclusion

  • Any history of treated or non-treated indolent lymphoma.
  • T-cell lymphoma.
  • Central nervous system or meningeal involvement by lymphoma.
  • Any Contra-indication to any drug contained in the chemotherapy regimens.
  • Poor renal function (creatinin level\>150µmol/l), poor hepatic function (total bilirubin level\>30mmol/l, transaminases\>2.5 maximum normal level) unless these abnormalities are related to the lymphoma.
  • Serious active disease (according to the investigator's decision).
  • Poor bone marrow reserve as defined by neutrophils \<1.5G/l or platelets\<100G/l, unless related to bone marrow infiltration.
  • Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.
  • Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study.
  • Childbearing woman.
  • Patients previously treated with an organ transplantation.

Key Trial Info

Start Date :

October 1 1999

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

300 Patients enrolled

Trial Details

Trial ID

NCT00169130

Start Date

October 1 1999

Last Update

July 13 2007

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Service d'Hematologie

Mont-Godinne, Belgium

2

Hôpital Henri Mondor

Créteil, France

3

Hôpital Saint Louis

Paris, France, 75010

4

Centre Hospitalier Lyon Sud

Pierre-Bénite, France